D-Index & Metrics Best Publications

D-Index & Metrics D-index (Discipline H-index) only includes papers and citation values for an examined discipline in contrast to General H-index which accounts for publications across all disciplines.

Discipline name D-index D-index (Discipline H-index) only includes papers and citation values for an examined discipline in contrast to General H-index which accounts for publications across all disciplines. Citations Publications World Ranking National Ranking
Medicine D-index 73 Citations 22,949 288 World Ranking 15589 National Ranking 548

Overview

What is he best known for?

The fields of study he is best known for:

  • Gene
  • Cancer
  • Mutation

Peter J. M. Valk mostly deals with Leukemia, Myeloid leukemia, Cancer research, Myeloid and Internal medicine. Peter J. M. Valk interconnects Haematopoiesis, Stem cell and Survival analysis in the investigation of issues within Leukemia. His work carried out in the field of Myeloid leukemia brings together such families of science as Hepatocyte growth factor, Tyrosine kinase, Molecular biology, MECOM and NPM1.

His work deals with themes such as Mutation, Transcription factor, CEBPA, Allele and Regulation of gene expression, which intersect with Cancer research. The concepts of his Myeloid study are interwoven with issues in Pathology and Gene expression profiling. His study in Internal medicine is interdisciplinary in nature, drawing from both Oncology and Chromosome 7.

His most cited work include:

  • Leukemic IDH1 and IDH2 mutations result in a hypermethylation phenotype, disrupt TET2 function, and impair hematopoietic differentiation. (1818 citations)
  • Prognostically useful gene-expression profiles in acute myeloid leukemia. (1170 citations)
  • DNA Methylation Signatures Identify Biologically Distinct Subtypes in Acute Myeloid Leukemia (639 citations)

What are the main themes of his work throughout his whole career to date?

His primary areas of study are Myeloid leukemia, Cancer research, Leukemia, Internal medicine and Myeloid. His biological study spans a wide range of topics, including Molecular biology, CEBPA, NPM1 and Gene expression profiling. His Cancer research research includes elements of DNA methylation, Mutation, Gene, Stem cell and Bone marrow.

His work investigates the relationship between Leukemia and topics such as Haematopoiesis that intersect with problems in Progenitor cell and microRNA. In the subject of general Internal medicine, his work in Hematology, Cytarabine and Transplantation is often linked to Hazard ratio, thereby combining diverse domains of study. His Myeloid research incorporates themes from Transcription factor and Cellular differentiation.

He most often published in these fields:

  • Myeloid leukemia (57.14%)
  • Cancer research (43.22%)
  • Leukemia (37.36%)

What were the highlights of his more recent work (between 2019-2021)?

  • Myeloid leukemia (57.14%)
  • Cancer research (43.22%)
  • Internal medicine (32.60%)

In recent papers he was focusing on the following fields of study:

Myeloid leukemia, Cancer research, Internal medicine, Oncology and Bone marrow are his primary areas of study. His Myeloid leukemia research integrates issues from Transcriptome, Gene expression, RNA, Epigenetics and Immunotherapy. His research in Cancer research is mostly concerned with Myeloid.

Peter J. M. Valk has included themes like Genocopy, Gene silencing, MECOM and Chromosomal translocation in his Myeloid study. The various areas that Peter J. M. Valk examines in his Oncology study include Discontinuation, MEDLINE, Gene, Tyrosine-kinase inhibitor and Cohort. Peter J. M. Valk combines subjects such as Regulation of gene expression and CEBPA with his study of GATA2.

Between 2019 and 2021, his most popular works were:

  • Immune landscapes predict chemotherapy resistance and immunotherapy response in acute myeloid leukemia (18 citations)
  • Comprehensive diagnostics of acute myeloid leukemia by whole transcriptome RNA sequencing (8 citations)
  • Lenalidomide added to standard intensive treatment for older patients with AML and high-risk MDS (8 citations)

In his most recent research, the most cited papers focused on:

  • Gene
  • Cancer
  • Mutation

His primary scientific interests are in Myeloid leukemia, Internal medicine, Cancer research, Oncology and Leukemia. Peter J. M. Valk has researched Myeloid leukemia in several fields, including Genocopy, Gene expression, Gene and Computational biology. Peter J. M. Valk is involved in the study of Cancer research that focuses on Myeloid in particular.

The study incorporates disciplines such as Immune system and Immunotherapy in addition to Oncology. His Immune system research is multidisciplinary, incorporating elements of Interleukin-3 receptor, Cancer, Antibody and Bone marrow. His Leukemia research is multidisciplinary, relying on both Arsenic trioxide, Cell cycle checkpoint, Cell growth, Acute promyelocytic leukemia and PI3K/AKT/mTOR pathway.

This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.

Best Publications

Leukemic IDH1 and IDH2 mutations result in a hypermethylation phenotype, disrupt TET2 function, and impair hematopoietic differentiation.

Maria E. Figueroa;Omar Abdel-Wahab;Chao Lu;Patrick S. Ward.
Cancer Cell (2010)

2654 Citations

Prognostically useful gene-expression profiles in acute myeloid leukemia.

Peter J.M. Valk;Roel G.W. Verhaak;M. Antoinette Beijen;Claudia A.J. Erpelinck.
The New England Journal of Medicine (2004)

1474 Citations

DNA Methylation Signatures Identify Biologically Distinct Subtypes in Acute Myeloid Leukemia

Maria E. Figueroa;Sanne Lugthart;Yushan Li;Claudia Erpelinck-Verschueren.
Cancer Cell (2010)

904 Citations

Mutations in nucleophosmin (NPM1) in acute myeloid leukemia (AML): Association with other gene abnormalities and previously established gene expression signatures and their favorable prognostic significance

Roel G. W. Verhaak;Chantal S. Goudswaard;Wim van Putten;Maarten A. Bijl.
Blood (2005)

825 Citations

Double CEBPA mutations, but not single CEBPA mutations, define a subgroup of acute myeloid leukemia with a distinctive gene expression profile that is uniquely associated with a favorable outcome

Bas J. Wouters;Bob Löwenberg;Claudia A. J. Erpelinck-Verschueren;Wim L. J. van Putten.
Blood (2009)

698 Citations

A Single Oncogenic Enhancer Rearrangement Causes Concomitant EVI1 and GATA2 Deregulation in Leukemia

Stefan Gröschel;Stefan Gröschel;Mathijs A Sanders;Remco Hoogenboezem;Elzo de Wit.
Cell (2014)

574 Citations

A 17-gene stemness score for rapid determination of risk in acute leukaemia

Stanley W. K. Ng;Amanda Mitchell;James A. Kennedy;James A. Kennedy;James A. Kennedy;Weihsu C. Chen.
Nature (2016)

541 Citations

Molecular Minimal Residual Disease in Acute Myeloid Leukemia

Mojca Jongen-Lavrencic;Tim Grob;Diana Hanekamp;François G Kavelaars.
The New England Journal of Medicine (2018)

533 Citations

MicroRNA expression profiling in relation to the genetic heterogeneity of acute myeloid leukemia.

Mojca Jongen-Lavrencic;Su Ming Sun;Menno K. Dijkstra;Peter J. M. Valk.
Blood (2008)

497 Citations

High Prognostic Impact of Flow Cytometric Minimal Residual Disease Detection in Acute Myeloid Leukemia: Data From the HOVON/SAKK AML 42A Study

Monique Terwijn;Wim L J van Putten;Angèle Kelder;Vincent H J van der Velden.
Journal of Clinical Oncology (2013)

449 Citations

If you think any of the details on this page are incorrect, let us know.

Contact us

Best Scientists Citing Peter J. M. Valk

Ross L. Levine

Ross L. Levine

Memorial Sloan Kettering Cancer Center

Publications: 107

Torsten Haferlach

Torsten Haferlach

MLL Munich Leukemia Laboratory

Publications: 103

Lars Bullinger

Lars Bullinger

Charité - University Medicine Berlin

Publications: 100

Hagop M. Kantarjian

Hagop M. Kantarjian

The University of Texas MD Anderson Cancer Center

Publications: 97

Hartmut Döhner

Hartmut Döhner

University of Ulm

Publications: 83

Guido Marcucci

Guido Marcucci

City Of Hope National Medical Center

Publications: 81

Clara D. Bloomfield

Clara D. Bloomfield

The Ohio State University

Publications: 80

Martin S. Tallman

Martin S. Tallman

Memorial Sloan Kettering Cancer Center

Publications: 79

Farhad Ravandi

Farhad Ravandi

The University of Texas MD Anderson Cancer Center

Publications: 72

Konstanze Döhner

Konstanze Döhner

University of Ulm

Publications: 70

Arnold Ganser

Arnold Ganser

Hannover Medical School

Publications: 70

Ari Melnick

Ari Melnick

Cornell University

Publications: 70

Claudia Haferlach

Claudia Haferlach

Ludwig-Maximilians-Universität München

Publications: 69

Daniel G. Tenen

Daniel G. Tenen

National University of Singapore

Publications: 68

Wolfgang Hiddemann

Wolfgang Hiddemann

Ludwig-Maximilians-Universität München

Publications: 66

Wolfgang Kern

Wolfgang Kern

Munich Leukemia Laboratory (Germany)

Publications: 65

Trending Scientists

Bergfinnur Durhuus

Bergfinnur Durhuus

University of Copenhagen

Yu Zhang

Yu Zhang

Southern University of Science and Technology

Ioannis Tsamardinos

Ioannis Tsamardinos

University of Crete

Antonio Morán

Antonio Morán

University of Leon

Philipp Adelhelm

Philipp Adelhelm

Humboldt-Universität zu Berlin

Henry M. Fales

Henry M. Fales

National Institutes of Health

Wei Pan

Wei Pan

Tsinghua University

Wen Zeng

Wen Zeng

Chongqing University

Roberto B. Figueiredo

Roberto B. Figueiredo

Universidade Federal de Minas Gerais

Mark P. Kamps

Mark P. Kamps

University of California, San Diego

L. Lacey Knowles

L. Lacey Knowles

University of Michigan–Ann Arbor

Santosh P. Lall

Santosh P. Lall

Lloyds Banking Group (United Kingdom)

Shimon Gatt

Shimon Gatt

Hebrew University of Jerusalem

Terrie E. Inder

Terrie E. Inder

Brigham and Women's Hospital

Erik Buskens

Erik Buskens

University Medical Center Groningen

Nils H. Turner

Nils H. Turner

Georgia State University

Something went wrong. Please try again later.